Previous 10 | Next 10 |
Implementing an appropriate strategy would capture the most profits. One such strategy is diversification. A promising stock for your portfolio to diversify is Alpine Immune Science. As a rising leader in immuno-oncology, Alpine has great medicines and has thus been able to secure thr...
Adaptimmune Therapeutics (NASDAQ:ADAP) is up 15% in trading on Wednesday and up ~21% since Monday's close as a likely beneficiary of Regeneron Pharmaceuticals' (REGN) $250M acquisition of Checkmate Pharmaceuticals (CMPI) announced Tuesday. Like Checkmate (CMPI), ...
Shares of the small-cap cancer companies Adaptimmune Therapeutics (NASDAQ: ADAP) , Agenus (NASDAQ: AGEN) , and Sorrento Therapeutics (NASDAQ: SRNE) all rose by more than 5% during Tuesday's trading session. Adaptimmune, Agenus, and Sorrento appear to be getting a muc...
Shares of clinical-stage biopharmaceutical company Adaptimmune Therapeutics (NASDAQ: ADAP) fell 14.7% on Monday, dropping to $1.86. The stock has a 52-week low of $1.69 and a 52-week high of $6.86. Image source: Getty Images. The company specializes in using cell therapies t...
Adaptimmune Therapeutics (NASDAQ:ADAP) files for $400M mixed shelf securities of the registrant’s ADSs, warrants and units. Also files agreement prospectus supplement covering the offering, issuance and sale of up to $200M between the registrant and Cowen and company. Stock...
Adaptimmune Therapeutics (NASDAQ:ADAP) has filed for a $400M mixed shelf offering. Shares are down 5% in after-hours trading. The filing does not necessarily indicate that a sale has begun, or will occur in the future. The company will outline the use of proceeds in a prospectu...
- Data from multiple solid tumor indications confirms that MAGE-A4 is a broadly expressed cancer target for SPEAR T-cell therapy - - Rate of eligible MAGE-A4 expression was 67% for synovial sarcoma, and ranged from 20%-35% for squamous cell lung, bladder, esophagogastric junction, ova...
Baker Brothers’ 13F portfolio value decreased from $22.77B to $20.55B this quarter. Incyte and Legend Biotech stakes were increased this quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~63% of the portfolio. For f...
Adaptimmune Therapeutics plc (ADAP) Q4 2021 Earnings Conference Call March 14, 2022 8:30 A.M. ET Company Participants Juli Miller - Investor Relations Adrian Rawcliffe - Chief Executive Officer Dennis Williams - Senior Vice President, Late Stage Development Elliot Norry - Chief Medical Office...
Adaptimmune press release (NASDAQ:ADAP): Q4 GAAP EPS of -$0.04 . Revenue of $1.4M (-6.7% Y/Y). As of December 31, 2021,the company had cash and cash equivalents of $149.9M Shares +7.14% PM. For further details see: Adaptimmune GAAP EPS of -$0.04, revenue of $1.4M
News, Short Squeeze, Breakout and More Instantly...
Adaptimmune Therapeutics plc Company Name:
ADAP Stock Symbol:
NASDAQ Market:
Adaptimmune Therapeutics plc Website:
Approved for advanced MAGE-A4+synovial sarcoma in adults with certain HLA types who have received prior chemotherapy TECELRA is the first new treatment option for people with synovial sarcoma in more than a decade Adaptimmune to hold webcast at https://www.gowebcasti...
2024-07-30 07:30:03 ET H.C. Wainwright analyst issues BUY recommendation for ADAP on July 30, 2024 06:07AM ET. ADAP was trading at $1.37 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 4 - Buy, 1 - Hold, ...
2024-07-30 07:00:10 ET Arthur He from H.C. Wainwright issued a price target of $4.00 for ADAP on 2024-07-30 06:07:00. The adjusted price target was set to $4.00. At the time of the announcement, ADAP was trading at $1.37. The overall price target consensus is at $2.54 wi...